ESSA Pharma (EPIX) Competitors

Amylyx Pharmaceuticals (NASDAQ:AMLX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Which has more risk & volatility, AMLX or EPIX?

Amylyx Pharmaceuticals has a beta of -0.68, indicating that its share price is 168% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Which has preferable earnings & valuation, AMLX or EPIX?

Amylyx Pharmaceuticals has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$196.49M	1.49	$49.27M	-$3.82	-1.12
ESSA Pharma	N/A	N/A	-$26.58M	-$0.62	-2.65

Does the media favor AMLX or EPIX?

In the previous week, ESSA Pharma had 1 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 5 mentions for ESSA Pharma and 4 mentions for Amylyx Pharmaceuticals. ESSA Pharma's average media sentiment score of 1.04 beat Amylyx Pharmaceuticals' score of 0.95 indicating that ESSA Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ESSA Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer AMLX or EPIX?

ESSA Pharma received 316 more outperform votes than Amylyx Pharmaceuticals when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 66.00% of users gave Amylyx Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amylyx Pharmaceuticals	Outperform Votes 33 66.00%	Underperform Votes 17 34.00%
ESSA Pharma	Outperform Votes 349 75.87%	Underperform Votes 111 24.13%

Is AMLX or EPIX more profitable?

ESSA Pharma has a net margin of 0.00% compared to Amylyx Pharmaceuticals' net margin of -17.86%. ESSA Pharma's return on equity of -20.17% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	-17.86%	-36.97%	-29.61%
ESSA Pharma	N/A	-20.17%	-19.62%

Do insiders and institutionals hold more shares of AMLX or EPIX?

95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are held by insiders. Comparatively, 14.7% of ESSA Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Do analysts recommend AMLX or EPIX?

Amylyx Pharmaceuticals presently has a consensus price target of $7.33, indicating a potential upside of 71.34%. ESSA Pharma has a consensus price target of $9.50, indicating a potential upside of 479.27%. Given ESSA Pharma's higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
ESSA Pharma	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

ESSA Pharma beats Amylyx Pharmaceuticals on 11 of the 18 factors compared between the two stocks.